UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
November 12, 2004
Date of Report (Date of earliest event reported)
CELL GENESYS, INC.
(Exact name of registrant as specified in its charter)
| | | | | |
Delaware
(State or other jurisdiction of
incorporation or organization) | | 0-19986
(Commission File Number) | | 94-3061375
(I.R.S. Employer
Identification Number) |
500 Forbes Boulevard
South San Francisco, CA 94080
(Address of principal executive offices, including zip code)
(650) 266-3000
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| o | | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o | | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o | | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
| o | | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
TABLE OF CONTENTS
Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off Balance Sheet Arrangement of a Registrant.
On November 12, 2004, pursuant to a 30-day option granted by Cell Genesys, Inc. (the “Company”) to J.P. Morgan Securities Inc. and Lehman Brothers Inc. (the “Initial Purchasers”) in a purchase agreement among the parties, the Company received notice that the Initial Purchasers elected to exercise in full their option to acquire an additional $35 million aggregate principal amount of the Company’s 3.125% Convertible Senior Notes due 2011. The private placement of these additional notes closed on November 17, 2004. Under certain circumstances, the Company may redeem some or all of the notes on or after November 1, 2009 at a redemption price equal to 100% of the principal amount of the notes. Holders of the notes may require the Company to repurchase some or all of their notes if a fundamental change occurs, at a repurchase price equal to 100% of the principal amount of the notes, plus accrued and unpaid interest (and additional amounts, if any) to, but not including, the repurchase date.
Item 3.02.Unregistered Sales of Equity Securities.
See disclosure under Item 2.03 above.
The Company expects to receive approximately $33.9 million in proceeds from the sale of the additional notes, after deducting the Initial Purchasers’ discount of approximately $1.1 million and estimated offering expenses. The Company intends to use the proceeds from the sale of the additional notes for general corporate purposes. The private placement was exempt from registration under the Securities Act of 1933, as amended, and pursuant to Section 4(2) thereof and Rule 144A promulgated thereunder.
The notes are convertible into the Company’s common stock, initially at the conversion price of $9.10 per share, equal to a conversion rate of approximately 109.8901 shares per $1,000 principal amount of notes, subject to adjustment.
Item 9.01. Financial Statements and Exhibits.
(c) Exhibits.
| | | |
| Exhibit | | |
No.
| | Description
|
| 99.1 | | Text of press release of Cell Genesys, Inc., dated November 17, 2004. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| | CELL GENESYS, INC.
| |
| Date: November 18, 2004 | By: | /s/ Matthew J. Pfeffer | |
| | | Name: | Matthew J. Pfeffer | |
| | | Title: | Vice President and Chief Financial Officer | |
| |
Exhibit Index
| | | |
| Exhibit | | |
No.
| | Description
|
| 99.1 | | Text of press release of Cell Genesys, Inc., dated November 17, 2004 |
